Viking Rises 25% in a Month: Should You Buy or Wait? - Eli Lilly ( NYSE:LLY ) , Madrigal Pharmaceuticals ( NASDAQ:MDGL )
Shares of Viking Therapeutics VKTX have soared nearly 25% in the past month, all thanks to progress with its investigational obesity and non-alcoholic steatohepatitis ( NASH ) candidates, which management plans to advance to late-stage development by early 2025.
| Ticker |
Sentiment |
Impact |
|
VKTX
|
Neutral
|
26 %
|
|
AZN
|
Neutral
|
4 %
|
|
NVO
|
Somewhat Bullish
|
12 %
|
|
LLY
|
Somewhat Bullish
|
15 %
|
|
MDGL
|
Neutral
|
8 %
|
|
GS
|
Neutral
|
4 %
|
|
PFE
|
Neutral
|
4 %
|
